TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Short-term Diaphragmatic Breathing Training Program in COPD Patients: a Randomized Controlled Trial
Brief Summary: Diaphragmatic dysfunction and alterations of thoracoabdominal motions are common in patients with chronic obstructive pulmonary disease (COPD). Several studies have described an impairment in diaphragmatic mobility of COPD patients compared to age matched control subjects and it has been associated with increase in dyspnea, exercise intolerance and mortality. COPD patients also experiment a higher activity of the accessory breathing muscles, which greatly increases the work of breathing and dyspnea sensation.

Breathing strategies have been considered an important component of pulmonary rehabilitation and refer to a range of techniques, including/which includes the diaphragmatic breathing (DB). The principal aim of DB is to improve the participation of the abdominal motion while reducing the accessory muscles activity. The role of DB as an adjunctive treatment modality in the rehabilitation of COPD patients remains controversial. Despite the conflicting results, improvement of the abdominal motion and a reduction of thoracic excursion, during voluntarily DB, has been described as a common finding of several studies. The investigators hypothesized that a 4-week DBTP could induce higher participation of the diaphragm and this modification would relieve respiratory symptoms and improve exercise tolerance and the HRQoL. Therefore, in this randomized controlled trial the investigators aimed to test the effects of a short-term DBTP on thoracoabdominal motion, pulmonary function, diaphragmatic mobility, dyspnea, HRQoL and exercise tolerance in patients with mild to severe COPD.


Options:
A: Arm Label: Activity-Self Management; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management and Motivational Interviewing | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-Management and Motivational Interviewing; Assigned to Arm(s): Activity-Self Management
B: Intervention Type: BEHAVIORAL; Name: Internet-based Dyspnea Self-Management Program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face Dyspnea Self-Management Program; Assigned to Arm(s): N/A
C: Arm Label: sPATH; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): sPATH
D: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diaphragmatic breathing training; Type: EXPERIMENTAL; Interventions: Other: Diaphragmatic breathing training | Intervention Type: OTHER; Name: Diaphragmatic breathing training; Assigned to Arm(s): Diaphragmatic breathing training

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Randomized Placebo-controlled Clinical Trial for the Efficacy and Safety of a Calcineurin Inhibitor, Tacrolimus(Prograf Cap®) in Patients With Non-nephrotic Albuminuric, Normotensive IgA Nephropathy
Brief Summary: This study is to evaluate efficacy and safety of tacrolimus in the patients with non-nephrotic albuminuric, normotensive IgA nephropathy after 16 week treatment with tacrolimus (Prograf) or placebo.


Options:
A: Arm Label: oral methylprednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): oral methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: prednisone + Inhibace/Cozaar; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Inhibace/Cozaar; Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive therapy with: ACE-inhibitor / ARB / Statin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive and immunosuppressive therapy | Intervention Type: DRUG; Name: supportive therapy with: ACE-inhibitor / ARB / Statin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: supportive and immunosuppressive therapy; Assigned to Arm(s): B
D: Arm Label: Tacrolimus group; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Tacrolimus group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Brief Summary: This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: LDP-02 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: LDP-02 | Intervention Type: DRUG; Name: LDP-02; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Brief Summary: This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.


Options:
A: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vedolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Vedolizumab | Arm Label: Vedolizumab 6 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Vedolizumab | Arm Label: Vedolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Vedolizumab | Intervention Type: DRUG; Name: Vedolizumab; Assigned to Arm(s): Vedolizumab 10 mg/kg, Vedolizumab 2 mg/kg, Vedolizumab 6 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Intravenous Dexmedetomidine on Spinal Anesthesia Using Low Dose Diluted Bupivacaine for Transurethral Resection of Prostate
Brief Summary: Dexmedetomidine is a new selective and potent alpha-2 agonist. It has centrally acting anesthetic properties. It has been known that intrathecal addition of alpha-2 adrenergic agents result in prolongation of the duration of the sensory and motor blockade induced by hyperbaric bupivacaine. But the effects of intravenous dexmedetomidine on the spinal block was not evaluated. The aim of study is to assess the effect of intravenous dexmedetomidine on the low-dose spinal anesthesia for the transurethral surgery.


Options:
A: Arm Label: Dex group; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine hydrochloride for injection | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% sodium chloride for injection | Intervention Type: DRUG; Name: dexmedetomidine hydrochloride for injection; Assigned to Arm(s): Dex group | Intervention Type: DRUG; Name: 0.9% sodium chloride for injection; Assigned to Arm(s): Placebo group
B: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA
C: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Placebo (PBO); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (PBO)
D: Arm Label: bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexmedetomidine | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): bupivacaine, saline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter Phase III Study to Assess the Efficacy of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
Brief Summary: The primary objectives of this study is to compare the efficacy of paclitaxel monotherapy with irinotecan monotherapy as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress following first line therapy.


Options:
A: Arm Label: Arm A: Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib plus capecitabine | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): Arm A: Lapatinib | Intervention Type: DRUG; Name: Lapatinib plus capecitabine; Assigned to Arm(s): Arm B
B: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)
C: Arm Label: paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel | Arm Label: irinotecan; Type: EXPERIMENTAL; Interventions: Drug: Irinotecan | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): paclitaxel | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): irinotecan
D: Arm Label: 1. PEP02; Type: EXPERIMENTAL; Interventions: Drug: PEP02 | Arm Label: 2. irinotecan; Type: ACTIVE_COMPARATOR; Interventions: Drug: irinotecan | Arm Label: 3. docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: docetaxel | Intervention Type: DRUG; Name: PEP02; Assigned to Arm(s): 1. PEP02 | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): 2. irinotecan | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): 3. docetaxel

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Fluid Management in Transient Tachypnea of the Newborn
Brief Summary: Transient tachypnea of the newborn (TTN) is a diagnosis given to infants born between 34 and 42 weeks gestation who develop difficulty breathing during the first days of life when no specific cause of the breathing difficulty can be identified. Little is known about why some babies develop TTN, and there have not been many formal studies of the best way to take care of babies with this disease. Babies with TTN get better on their own within three to five days after birth, but may require extra oxygen to breath well.

Most physicians believe that the symptoms of TTN are related to poor clearance of fluid from the newborn's lungs. Babies with TTN have extra fluid visible on chest x-ray. Diuretics, medicines that can help clear extra lung fluid in adults and in babies with extra lung fluid for other reasons, do not to help babies with TTN. Babies with TTN need intravenous fluids to be healthy because they breathe too fast to be able to eat. Breastfed babies only get a very small amount of fluid in the first few days of life, as it normally takes several days for a new mother to begin producing breastmilk. No one has yet examined whether giving babies with TTN an amount of fluid similar to the small amount they would receive if they could breastfeed would help them recover from TTN faster.

In this study, the investigators compare whether giving newborns "standard" intravenous fluid or amounts of intravenous fluid more close to what a breastfed baby would receive speeds recovery in newborns with TTN.


Options:
A: Arm Label: Standard Fluids; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Restricted Fluids; Type: EXPERIMENTAL; Interventions: Other: Amount of total fluids | Intervention Type: OTHER; Name: Amount of total fluids; Assigned to Arm(s): Restricted Fluids
B: Arm Label: Inhaled steroids (Budicort); Type: EXPERIMENTAL; Interventions: Drug: Experimental group: Budicort by Inhalation | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Experimental group: Budicort by Inhalation; Assigned to Arm(s): Inhaled steroids (Budicort) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Control
C: Arm Label: nHFPV; Type: EXPERIMENTAL; Interventions: Procedure: Intrapulmonary Percussive Ventilation | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nasal Continuous Positive Airway Pressure ventilation | Intervention Type: PROCEDURE; Name: Nasal Continuous Positive Airway Pressure ventilation; Assigned to Arm(s): nCPAP | Intervention Type: PROCEDURE; Name: Intrapulmonary Percussive Ventilation; Assigned to Arm(s): nHFPV
D: Arm Label: Neopuff group; Type: EXPERIMENTAL; Interventions: Device: Neopuff | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Neopuff; Assigned to Arm(s): Neopuff group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis
Brief Summary: The aim of this study is to study the comparison between the effects of supplementation with 25000 IU preformed vitamin A (retinyl palmitate) or placebo for 6 months on immune system and Th1/Th2 balance in patients with Multiple Sclerosis.


Options:
A: Arm Label: with Multiple Sclerosis/ vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin A | Arm Label: with Multiple Sclerosis/ placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): with Multiple Sclerosis/ vitamin A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): with Multiple Sclerosis/ placebo
B: Arm Label: vitamin A, multiple sclerosis,; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin A, Drug: Drug: placebo | Arm Label: placebo/Multiple Sclerosis; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A; Assigned to Arm(s): placebo/Multiple Sclerosis, vitamin A, multiple sclerosis, | Intervention Type: DRUG; Name: Drug: placebo; Assigned to Arm(s): vitamin A, multiple sclerosis,
C: Arm Label: Fish oil concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fish oil concentrate | Arm Label: Placebo oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fish oil concentrate; Assigned to Arm(s): Fish oil concentrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo oil
D: Arm Label: Green tea extract; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Capsules with 160 mg Teavigo (at least 94% EGCG) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Capsules with 160 mg Teavigo (at least 94% EGCG); Assigned to Arm(s): Green tea extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Brief Summary: This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo) | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo) | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Matching placebo for Rivaroxaban arm (Warfarin placebo); Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Matching placebo for Warfarin arm (Rivaroxaban placebo); Assigned to Arm(s): Warfarin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 90 mg | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 60 mg | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ticagrelor Placebo | Intervention Type: DRUG; Name: Ticagrelor 90 mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ticagrelor 60 mg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ticagrelor Placebo; Assigned to Arm(s): 3
C: Arm Label: ischemic heart disease; Type: N/A; Interventions: N/A | Arm Label: non-ischemic heart disease; Type: N/A; Interventions: N/A
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Omeprazole; Type: EXPERIMENTAL; Interventions: Drug: Omeprazole | Arm Label: Placebo (dabigatran); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dabigatran) | Arm Label: Placebo (omeprazole); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Omeprazole) | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Placebo (for Dabigatran); Assigned to Arm(s): Placebo (dabigatran) | Intervention Type: DRUG; Name: Omeprazole; Assigned to Arm(s): Omeprazole | Intervention Type: DRUG; Name: Placebo (for Omeprazole); Assigned to Arm(s): Placebo (omeprazole)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction
Brief Summary: This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).


Options:
A: Arm Label: Aggrenox; Type: EXPERIMENTAL; Interventions: Drug: Aggrenox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Drug therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Medical therapy | Arm Label: Drug therapy + stenting angioplasty; Type: EXPERIMENTAL; Interventions: Procedure: stenting angioplasty plus medical therapy | Intervention Type: PROCEDURE; Name: stenting angioplasty plus medical therapy; Assigned to Arm(s): Drug therapy + stenting angioplasty | Intervention Type: DRUG; Name: Medical therapy; Assigned to Arm(s): Drug therapy
C: Arm Label: TRK-100STP; Type: EXPERIMENTAL; Interventions: Drug: TRK-100STP high dose, Drug: TRK-100STP low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TRK-100STP high dose; Assigned to Arm(s): TRK-100STP | Intervention Type: DRUG; Name: TRK-100STP low dose; Assigned to Arm(s): TRK-100STP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 90 mg | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 60 mg | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ticagrelor Placebo | Intervention Type: DRUG; Name: Ticagrelor 90 mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ticagrelor 60 mg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ticagrelor Placebo; Assigned to Arm(s): 3

Answer: D